27
Participants
Start Date
May 31, 2011
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
PF-04171327
Oral single 5 mg dose as one 5 mg tablet
PF-04171327
Oral single 10 mg dose as one 10 mg tablet
PF-04171327
Oral single 30 mg dose as three 10 mg tablets
Placebo
Oral single dose as matching placebo
PF-04171327
Oral multiple 20 mg doses as two 10 mg tablets for 12 days
Placebo
Oral multiple doses as matching placebo for 12 days
Pfizer Investigational Site, Glendale
Lead Sponsor
Pfizer
INDUSTRY